Long term survival in a patient with recurrent metastatic Ewing sarcoma treated with irinotecan and temozolomide

• Main Authors: Hakan Gelincik, Serhan Kupeli
• Format: Article
• Language: English
• Published: Cukurova University 2016-12-01
• Series: Çukurova Üniversitesi Tıp Fakültesi Dergisi
• Subjects: Ewing Sarcoma; irinotecan; temozolomide
• Online Access: http://www.scopemed.org/fulltextpdf.php?mno=227350

Ewing sarcoma family of tumor is the second most common bone tumor in children and young adults, after osteosarcoma. Different chemotherapeutic regimens are used in treatment of relapsed/recurrent Ewing sarcoma. Promising results were achieved with combination of irinotecan and temozolomide. Our case was a 13-year-old female with relapsed Ewing sarcoma and after 12 cycles of irinotecan (20 mg/m2/10 days) and temozolomide (100mg/m2/5 days) treatment she had not any complaints, and her radiological lesions remained stable for 66 months. Irinotecan and temozolomide have been used successfully in treatment of relapsed/recurrent Ewing sarcoma, but there is a need for randomized prospective studies with larger patient groups for establishing the efficacy of this treatment protocol. [Cukurova Med J 2016; 41(4.000): 811-814]